Carfilzomib-Induced Tumor Lysis Syndrome and Biventricular Heart Failure in a Patient With Multiple Myeloma

Carfilzomib is a proteasome inhibitor (PI) used in multiple myeloma (MM) that is resistant to other therapies. Despite its efficacy and potency, carfilzomib has been associated with kidney injuries, cardiovascular toxic effects, and hematological adverse events. Tumor lysis syndrome (TLS) following...

Descripción completa

Detalles Bibliográficos
Autores principales: Azad, Farhan, Moyer, Ross, Miranda, Clive J, Gravina, Matthew
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2023
Materias:
Cardiology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9907735/
https://www.ncbi.nlm.nih.gov/pubmed/36779143
http://dx.doi.org/10.7759/cureus.33538

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9907735/
https://www.ncbi.nlm.nih.gov/pubmed/36779143
http://dx.doi.org/10.7759/cureus.33538

Ejemplares similares